Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 230 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: N Acetyl Cysteine Clear all

Conditions: Carpal Tunnel Surgery, Trigger Finger Disorder, De Quervain Syndrome, Guyon's Canal, Dupuytren Contracture, Morton Neuroma, Tarsal Tunnel Syndrome, Plantar Fasciopathy, Peroneal Nerve Entrapment
Interventions: NAC, NAC 0mg/day (Placebo); Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Radiocontrast Nephropathy
Interventions: N-Acetylcysteine (NAC), 0.9% Sodium-chloride; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: End-Stage Renal Disease, Dialysis, Hemodialysis
Interventions: N-acetylcysteine, placebo; Dietary Supplement
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cystic Fibrosis
Interventions: N-acetylcysteine (NAC), Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 7 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 11
States / cities: Birmingham, Alabama • Stanford, California • Denver, Colorado + 8 more

Conditions: Acute Liver Failure, Hepatic Encephalopathy
Interventions: N-acetylcysteine, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: Up to 18 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 17
States / cities: San Francisco, California • Denver, Colorado • Atlanta, Georgia + 13 more

Conditions: Oxidative Stress
Interventions: Placebo low dose, N Acetyl cysteine, 600mg (low dose), Proimmune 200 (FT061452) 3000mg low dose, Placebo (high dose), N Acetyl cysteine, 1200mg (high dose), FT061452, 6000mg high dose; Drug
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 30 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pharmacokinetics
Interventions: NAC, Neuro-NAC, Neuro-NAC XS; Dietary Supplement
Lead sponsor: University of Memphis; Other
Eligibility: 18 Years to 45 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Malignant Ovarian Endometrioid Tumor, Malignant Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Topotecan Hydrochloride, Acetylcysteine; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pulmonary Sarcoidosis
Interventions: N-acetyl-cysteine, Placebo; Dietary Supplement · Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Bipolar Disorder
Interventions: Open-label Treatment with N-Acetylcysteine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 5 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acetaminophen Toxicity
Interventions: Not listed
Lead sponsor: Akron Children's Hospital; Other
Eligibility: 1 Month to 21 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Retinitis Pigmentosa
Interventions: N-Acetyl Cysteine (NAC); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Liver Failure
Interventions: N-acetylcysteine (NAC), Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 25
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 19 more

Conditions: Bipolar Disorder, Bipolar I Disorder, Bipolar II Disorder
Interventions: N-Acetyl cysteine, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: HIV, Endothelial Dysfunction, Oxidative Stress
Interventions: PharmaNAC (N-acetylcysteine), Matching placebo; Dietary Supplement
Lead sponsor: Indiana University; Other
Eligibility: 50 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Infant of Diabetic Mother, Oxidative Stress, Vagus Nerve Stimulation, Feeding Disorders
Interventions: N acetyl cysteine + vagus nerve stimulation; Combination Product
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 3 Weeks to 5 Months
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Autism Spectrum Disorder
Interventions: N acetyl cysteine, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 3 Years to 12 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Obstructive Sleep Apnea
Interventions: N-acetylcysteine (NAC), Placebo, Positive Airway Pressure (PAP) Therapy; Dietary Supplement · Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 55 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Aging
Interventions: N-acetylcysteine, Losartan, Placebo losartan, Placebo N-acetylcysteine; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 60 Years to 85 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Graft vs Host Disease
Interventions: Begelomab, Conventional Second-line Treatment; Biological
Lead sponsor: Adienne SA; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 10
States / cities: Duarte, California • Westwood, Kansas • Boston, Massachusetts + 7 more

Conditions: HIV Infection, Erythrocyte Glutathione Deficiency
Interventions: GlyNAC (combination of glycine and n-acetylcysteine); Dietary Supplement
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 45 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)
Interventions: rifaximin 66mg + N-acetylcysteine 560mg three times daily, RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily, Placebo; Drug
Lead sponsor: Mark Pimentel, MD; Other
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypertension, Cardiovascular Diseases
Interventions: Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals.; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 21 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Alcohol Use Disorder
Interventions: Alcohol, Placebos, N-acetyl cysteine; Drug
Lead sponsor: William Stoops; Other
Eligibility: 21 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Lexington, Kentucky

Search by objective public record fields.

NAC-REPAIR for Post-surgical Pain

N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients

Effects of N-acetylcysteine on Muscle Fatigue in Hemodialysis

NAC Phase IIB: A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients

N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure

The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels

Pharmacokinetic Profile of N-Acetyl Cysteine

Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis

Open-Label Study of N-Acetylcysteine in Children and Adolescents 5-17 With Bipolar Spectrum Disorders

Treatment of APAP Toxicity With IV and Oral NAC 2008-2011

The FIGHT-RP1 Study

Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen

Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder

N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults

NAC +taVNS in IDM Who Are Poor Oral Feeders

Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial

Obstructive Sleep Apnea (OSA) and Sex-Specific Responses to N-acetylcysteine (NAC)

Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative Stress in Elderly

Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD

Glutathione and Function in HIV Patients

Efficacy of Rifaximin With NAC in IBS-D

Effect of Sublingually Generated S-nitroso-N-acetylcysteine on Systemic Blood Pressure.

Influence of n-Acetylcysteine Maintenance on Alcohol Effects